The WTO's TRIPS Agreement exported U.S. and European IP standards to the entire developing world. Developing countries pushed back. The HIV/AIDS access crisis showed the stakes. Here's how the global IP system works — and why it remains contested.
Educational content only — not personalized financial, legal, or tax advice.
Before 1995, intellectual property protection varied enormously across countries. India had no pharmaceutical product patents, allowing it to manufacture and export generic versions of patented drugs at a fraction of branded prices. Brazil had weak enforcement of software copyrights. Many developing countries had minimal patent protection, making them attractive manufacturing bases for products that could be sold globally without royalty payments.
The WTO's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which entered into force in 1995 as part of the Uruguay Round that created the WTO, changed this. TRIPS established minimum standards for IP protection that all WTO members — now 164 countries — were required to implement. Patent protection of at least 20 years. Copyright protection of at least life plus 50 years. Criminal penalties for piracy and counterfeiting.
For the U.S. and EU pharmaceutical, software, and entertainment industries, TRIPS was a major victory. For developing countries, it was the imposition of a system designed by and for the world's wealthiest economies — with costs that became viscerally clear within a few years. This connects to the pharmaceutical patent economics covered earlier in this series and to how the global corporate ownership system functions.
By the late 1990s, antiretroviral therapy (ART) had transformed HIV/AIDS from a death sentence to a manageable chronic condition in wealthy countries. A course of ART cost approximately $10,000-15,000 per patient per year at branded prices. Sub-Saharan Africa, which had 70% of the world's HIV infections, had per capita incomes of $500-2,000 per year. The arithmetic was genocidal.
India, Brazil, Thailand, and South Africa had been manufacturing generic antiretrovirals and supplying them to developing world patients at $350 per year or less. TRIPS threatened to end this: as they implemented pharmaceutical patent protection, they would lose the ability to manufacture these drugs without paying royalties to patent holders that neither their governments nor their patients could afford.
The tension came to a head at the WTO's Doha Ministerial in 2001. Under enormous pressure from NGOs, the African Group, and public opinion, WTO members adopted the Doha Declaration on TRIPS and Public Health — clarifying that TRIPS allows member countries to issue compulsory licenses (authorizing local manufacture of patented drugs without the patent holder's consent) and to use other flexibilities to protect public health.
Specifically, Doha affirmed:
The Doha Declaration saved millions of lives. The scale of generic ART that followed — produced primarily by Indian manufacturers like Cipla, Dr. Reddy's, and Sun Pharma — dramatically reduced HIV/AIDS mortality across Africa. By 2006, generic ART was available for under $100 per patient per year.
India's implementation of TRIPS was the most consequential national IP decision of the past 30 years. India introduced pharmaceutical product patents in 2005 (previously only process patents were allowed) but included a provision unique in global patent law: Section 3(d) of the Patents Act.
Section 3(d) prevents the grant of patents for new forms (polymorphs, salts, isomers, combinations) of known substances unless the applicant demonstrates significantly enhanced efficacy. This directly targets the pharmaceutical evergreening strategy — minor reformulations of existing drugs to extend patent exclusivity — by requiring meaningful therapeutic improvement before additional patents are granted.
Novartis challenged Section 3(d) when it was denied a patent for Gleevec (imatinib), a cancer drug, arguing the Indian provision violated TRIPS. The Indian Supreme Court upheld Section 3(d) in 2013, rejecting Novartis's challenge. The ruling was globally significant: it established that TRIPS flexibilities allow countries to design patent systems that balance innovation incentives against public health access.
India's generic pharmaceutical industry, shaped by this legal environment, is now the world's pharmacy for developing countries: India produces approximately 20% of global generic medicines by volume and supplies 62% of global vaccine demand. Its pharmaceutical exports exceed $25 billion annually. The semiconductor industry equivalent — TSMC's dominance in chip manufacturing — shows how national industrial policy can create globally dominant sectors.
Pharmaceuticals are the highest-stakes area of the global IP debate, but the TRIPS framework covers all IP. In software and entertainment, the global IP system generates different tensions.
Software piracy rates in developing countries remain very high by developed-country standards. The BSA (Business Software Alliance) estimates global software piracy at approximately $46 billion annually. From one perspective, this represents lost revenue for U.S. and European software companies. From another perspective, the piracy of software that would otherwise be unaffordable in developing country markets can be understood as an informal form of technology transfer — building digital skills and infrastructure on software platforms that legitimate access programs would never deliver at scale.
The entertainment industry's global IP enforcement efforts have produced the largest copyright litigation in history. The Recording Industry Association of America's early-2000s campaign of lawsuits against individual file-sharers — including a $222,000 judgment against a single mother in Minnesota for sharing 24 songs — was a public relations catastrophe that did nothing to slow digital piracy while generating enormous hostility toward the music industry.
The global IP system faces its most fundamental challenge from AI: who owns what a machine creates?
The U.S. Copyright Office has issued guidance stating that AI-generated content is not copyrightable — copyright requires human authorship. But the line between AI-generated and AI-assisted content is contested. A photographer who uses AI to generate a background element in an otherwise human-created image — is that copyrightable? A novelist who uses AI to draft an outline that they then substantially rewrite? The legal boundaries are unsettled globally.
The training data question is equally unresolved. AI systems trained on copyrighted content — books, images, code, music — raise the question of whether that training constitutes infringement. Multiple lawsuits in the U.S. and EU are working through this question. The outcome will shape the economics of AI development — either requiring licensing payments to content creators that significantly increase training costs, or establishing that training is fair use and creating no obligation to content owners whose work built the systems.
These are not abstract legal questions. They're economic questions about who captures the value created by AI systems — and they connect directly to the future of creative industries and to the broader economic disruption AI is producing.